Gilead clears GMP violations amid HIV drug approval

AIDS drugmaker Gilead Sciences says it has cleaned its slate with the FDA. The Foster City, CA company "has resolved all outstanding issues" from a warning letter of a year ago concerning its San Dimas, CA, plant, according to a statement.

Among the issues identified in the warning were "excessive body and hand movements and animated conversations" of an aseptic fill operator in violation of procedures "to make slow, deliberate movements during manufacturing operations" to avoid microcontamination. Another citation: lack of investigation into a product failure involving tablet-process re-validation lots that repeatedly failed visual inspection. Rather than investigating the cause, operators culled defective tablets and packaged the remainder.

The warning letter also contained multiple instances of the word "inadequate" to describe Gilead's proposed fixes to shortcoming identified during the inspection.

However, Gilead has been grabbing headlines recently for its successful collaboration with Johnson & Johnson on Complera. The HIV treatment combines Gilead's Truvada and J&J's Edurant into a once-daily pill and gained FDA market approval this month.

- read the Gilead statement
- here's Warning Letter W/L 44-10 to General Manager Robert Hull

Special Report: Frightening Phrases: Warning letter language to watch

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.